Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836231 | 1.00 | APP (0.66) | APPPTGS2PTGS1MAOBGAA | |
| SCHEMBL2831598 | 0.92 | PTGS2 (0.62) | APPPTGS2PTGS1MAOBGAA | |
| SCHEMBL9156442 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1MAOBGAAMEN1 | |
| SCHEMBL9156438 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1MAOBGAAMEN1 | |
| SCHEMBL2828900 | 0.81 | PTGS2 (0.50) | APPPTGS2PTGS1MAOBMEN1 | |
| SCHEMBL2828898 | 0.81 | PTGS2 (0.50) | APPPTGS2PTGS1MAOBMEN1 | |
| SCHEMBL2831077 | 0.80 | APP (1.00) | APPMAOBMAPTNPC1LMNA | |
| SCHEMBL13096201 | 0.79 | PTGS2 (0.52) | APPPTGS2PTGS1MAOBMEN1 | |
| SCHEMBL3971713 | 0.77 | PTGS2 (0.60) | PTGS2PTGS1MAOBGAAMEN1 | |
| SCHEMBL9335748 | 0.76 | PTGS2 (0.68) | APPPTGS2PTGS1MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858072-B2 | Stilbene derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-12-28 | — | — | US | disclosed |
| US-20060269474-A1 | Stilbene derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060269474-A1 | Stilbene derivatives and their use for binding and imaging amyloid plaques | APP, APBA1, PSEN1 | APP 1/4885PTGS2 3442/4885PTGS1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.